Targeted radiation for advanced skin tumors with a nano-therapy
Part of Cancer, Skin clinical trials.
This Phase 1/2 study tests an “Auger molecular therapy” treatment that uses targeted radiation on certain advanced cancers that have spread to the skin. It may help shrink or control skin tumors where the lesion size and location fit the treatment device.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer diagnosis must be one of these: head and neck, breast, gastrointestinal, pancreatic, gallbladder, liver, endometrial, or prostate—and it must have spread to the skin or grown into the skin from nearby.
- Your skin lesion must be a certain size and thickness (up to 6 cm across, and 0.7 cm thick or less) so the device can cover it safely.
- Your lesion must be measurable by a specific imaging/marking method the study team will use.
- You must be able to lie or sit in a cast/positioning setup for 25 minutes (and not be unable to tolerate this).
- Your blood counts, liver, and kidney tests must meet required safety ranges, and you must not have certain high-risk conditions (like pregnancy, HIV, or areas near sensitive body parts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
This early-phase study tests whether delivering chemotherapy through tiny skin needles (microneedles) can shrink or control cutaneous squamous cell cancer (cSCC) that can be surgically treated. Because it’s Phase 1/2, the main goals are to check safety and find the best way to deliver the treatment.
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
This study tests a new type of radiation therapy, called minibeam radiation, for skin or soft tissue tumors that have come back or spread. The goal is to see if this approach can help shrink tumors while possibly sparing healthy tissue, and it's designed for people who may benefit from palliative treatment to relieve symptoms.
This Phase 1 study tests a new way to make radiation work better using MRI-guided focused ultrasound. It focuses on improving treatment for malignant melanoma and other skin cancers, while checking safety and how patients experience treatment.
This study tests a new treatment combining gold nanoparticles (Au-TMP), radiation therapy, and an immune-boosting drug (anti-PD-1) for advanced melanoma that cannot be surgically removed. The goal is to help your immune system fight the cancer more effectively.
Hear when a new Malignant Fungating Wound trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.